White Pine Capital LLC Invests $1.79 Million in Independent Bank Corp. $INDB
White Pine Capital LLC has invested $1.79 million in Independent Bank Corp. by purchasing 25,904 shares, representing approximately 0.05% of the company. Independent Bank (NASDAQ: INDB) has a market capitalization of $4.14 billion, recently reported an earnings beat of $1.70 EPS against a $1.65 consensus, and pays a quarterly dividend of $0.59 (2.8% yield). The stock carries a consensus "Hold" rating with a target price of $76.50.
Mitsubishi UFJ Asset Management UK Ltd. Purchases 2,500 Shares of Intuitive Surgical, Inc. $ISRG
Mitsubishi UFJ Asset Management UK Ltd. significantly increased its stake in Intuitive Surgical, Inc. by 138.9% in the third quarter, purchasing an additional 2,500 shares to own a total of 4,300 shares valued at approximately $1.923 million. This makes Intuitive Surgical the fund's 29th largest position, accounting for 0.9% of its portfolio. Concurrently, company insiders have been net sellers, offloading over 56,000 shares worth about $30.8 million, while analysts maintain a "Moderate Buy" rating with an average target price of $617.23.
Raiffeisen Bank International AG Has $26.66 Million Position in Core & Main, Inc. $CNM
Raiffeisen Bank International AG increased its stake in Core & Main, Inc. (NYSE:CNM) by 3.8% in Q3, now owning 497,051 shares valued at $26.66 million. Institutional investors collectively own 94.19% of Core & Main, with notable new positions from Norges Bank and Jennison Associates. Core & Main recently beat Q3 EPS estimates, announced a $500 million share buyback, and has an average "Moderate Buy" rating from analysts with a target price of $62.00.
Beam Therapeutics (NASDAQ:BEAM) Upgraded at Canaccord Genuity Group
Canaccord Genuity Group has upgraded Beam Therapeutics (NASDAQ:BEAM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating among analysts with an average target price of $45.69. The gene-editing company's stock has seen recent trading activity, including an insider sale by Christine Bellon in January, and significant institutional investor interest. Beam Therapeutics, known for its pioneering base editing platform, aims to develop precision genetic medicines.
King Luther Capital Management Corp Grows Stake in Boston Scientific Corporation $BSX
King Luther Capital Management Corp significantly increased its holdings in Boston Scientific Corporation by 350.6% in the third quarter, bringing their total stake to 46,851 shares valued at $4,574,000. Several other institutional investors also adjusted their positions in BSX. Concurrently, Boston Scientific insiders, including the CEO and EVP, sold significant amounts of company stock.
GSA Capital Partners LLP Makes New Investment in Herbalife Ltd $HLF
GSA Capital Partners LLP has initiated a new investment in Herbalife Ltd ($HLF), acquiring over 107,000 shares valued at approximately $911,000. This comes as Herbalife recently reported mixed Q4 earnings, with revenue exceeding expectations but EPS missing consensus. The company's stock has seen a positive market reaction, rallying to multi-year highs, supported by a minority investment from Cristiano Ronaldo and several analyst upgrades, with a consensus price target of $16.60.
JPMorgan Chase & Co. Sells 467,516 Shares of Mid-America Apartment Communities, Inc. $MAA
JPMorgan Chase & Co. reduced its stake in Mid-America Apartment Communities, Inc. (MAA) by 23.1%, selling 467,516 shares. Despite missing quarterly EPS estimates and having an elevated dividend payout ratio, MAA's stock trades near $133 with a "Hold" consensus rating and a recently increased quarterly dividend. Other institutional investors have adjusted their positions, and insider transactions have also occurred.
JPMorgan Chase & Co. Grows Position in Encompass Health Corporation $EHC
JPMorgan Chase & Co. increased its stake in Encompass Health Corporation by 5.3% in Q3, now owning 1,410,335 shares valued at $179.14 million. This comes as Encompass Health reported strong Q4 earnings, beating expectations with $1.46 EPS and revenue of $3.09 billion, and set optimistic FY2026 guidance. Despite a significant insider sale by CEO Mark J. Tarr, analyst sentiment remains largely positive with a "Buy" consensus rating for the company.
HighTower Advisors LLC Has $11.96 Million Position in Royal Bank Of Canada $RY
HighTower Advisors LLC significantly increased its stake in Royal Bank of Canada (RY) by 11.9% in Q3, now holding 81,188 shares valued at approximately $11.96 million. The Royal Bank of Canada stock holds a "Moderate Buy" consensus rating from analysts with a target price of $162.00, and recently reported strong quarterly earnings, beating estimates with EPS of $2.76 and revenue of $12.27 billion, alongside raising its quarterly dividend to $1.64.
iQIYI, Inc. Sponsored ADR (NASDAQ:IQ) Receives Consensus Rating of "Hold" from Analysts
Four analysts have given iQIYI, Inc. Sponsored ADR (NASDAQ:IQ) a consensus "Hold" rating, with an average 12-month target price of $2.64. Recent analyst sentiment has shown downside pressure, including a "strong sell" from Zacks. Despite this, institutional ownership stands at 52.69%, with significant recent buys from firms like Marshall Wace, as the stock trades near $1.82 with a $1.75 billion market cap.
Envestnet Asset Management Inc. Acquires 290,229 Shares of Cushman & Wakefield PLC $CWK
Envestnet Asset Management Inc. significantly increased its stake in Cushman & Wakefield PLC, acquiring an additional 290,229 shares in Q3, bringing its total to 476,359 shares valued at $7.58 million. This comes as Cushman & Wakefield reported strong Q4 results, beating revenue and EPS expectations, and is focusing on capital markets growth and AI initiatives, including a new AI-momentum model. The company maintains a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $18.56.
MDxHealth SA (NASDAQ:MDXH) Given Average Rating of "Moderate Buy" by Analysts
MDxHealth SA (NASDAQ:MDXH) has received an average "Moderate Buy" rating from analysts, with an average one-year price target of $7.75. This consensus stems from five research firms, including one sell rating and four buy ratings. The molecular diagnostics company, focusing on urological cancers, opened at $3.63 with a market cap of $171.7M and a negative P/E of -5.67.
Hanmi Financial Corporation (NASDAQ:HAFC) Receives Average Recommendation of "Hold" from Brokerages
Hanmi Financial Corporation (NASDAQ:HAFC) has received an average "Hold" recommendation from five brokerages, with an average 1-year price target of $31.33. The bank recently raised its quarterly dividend to $0.28, representing a 4.1% yield. Despite missing EPS estimates slightly, they reported revenue above consensus and institutional investors hold a significant portion of shares.
Aberdeen Group plc Makes New Investment in Palvella Therapeutics, Inc. $PVLA
Aberdeen Group plc has made a new investment in Palvella Therapeutics, Inc. (NASDAQ:PVLA), purchasing 51,243 shares valued at approximately $3.21 million, now owning 0.46% of the company. Institutional investors collectively hold about 40.11% of the stock, and Wall Street analysts maintain a consensus "Buy" rating with an average target price of $158.69.
Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen
Wall Street Zen upgraded Medtronic (NYSE:MDT) to a "buy" rating, reflecting a "Moderate Buy" consensus among analysts with an average target price of $111.05. This upgrade follows Medtronic's slight beat on Q3 earnings and revenue estimates, alongside strong institutional buying, including a significant new position from Norges Bank. The article also details recent analyst actions, financial performance metrics, and various market sentiments impacting the company.
Banco Bilbao Viscaya Argentaria (NYSE:BBVA) Raised to "Buy" at Wall Street Zen
Wall Street Zen has upgraded Banco Bilbao Viscaya Argentaria (NYSE:BBVA) to a "buy" rating from "hold," leading to a current average rating of "Moderate Buy" among analysts. This upgrade follows strong Q4 earnings where the company met EPS estimates of $0.50 and exceeded revenue forecasts with $11.49 billion, demonstrating robust profitability. The stock's valuation shows a market cap of $135.48 billion, a P/E of 11.93, and a PEG of 0.81, with its stock price recently trading around $23.51.
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday
Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($0.14) per share. The company's stock shows a 52-week range of $0.62–$2.93 and a market cap of $356.19 million, with notable institutional ownership. Wall Street analysts currently hold an average "Sell" rating for NAUT with a target price of $2.50.
ARMOUR Residential REIT (NYSE:ARR) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded ARMOUR Residential REIT (NYSE:ARR) from "hold" to "sell," despite other analysts having mixed ratings, leading to a MarketBeat consensus of "Hold" with an $18.17 target price. The company reported Q4 distributable EPS of $0.71, missing consensus, but saw a full-year 2025 net income of $322.7M, grew its MBS portfolio by 60%, and maintained a $0.24 monthly dividend. Shares are trading around $17.89, with a P/E ratio of 6.55, and an insider recently sold shares.
Tevogen Bio (TVGN) to Release Earnings on Wednesday
Tevogen Bio (TVGN) is set to release its earnings on Wednesday, February 25th, with analysts forecasting a loss of ($0.03) per share. The stock currently trades around $0.28, reflecting its volatile small-cap profile and a market capitalization of approximately $55.8 million. Despite mixed analyst ratings of one Buy and one Sell, resulting in a consensus Hold, institutional investors like Bridgeway, Deutsche Bank, and Goldman Sachs have recently increased their stakes.
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics CEO Howard Robin recently sold 423 shares of NKTR stock on February 18th for $73.00 per share, reducing his stake by 0.56%. Following this transaction, Robin now owns 75,489 shares valued at approximately $5.51 million. The stock is trading near its 12-month high of $74.89, with a market capitalization of $1.50 billion.
Important takeaways from Medtronic’s (MDT) Q3 2026 earnings report
Medtronic (MDT) reported stronger-than-expected Q3 2026 earnings, but its shares declined due to weaker margins and a cautious full-year outlook. The company's revenue increased by 8.7% to $9.0 billion, exceeding analyst estimates, driven by strong performance in cardiovascular and neuroscience segments. Medtronic reaffirmed its full-year organic revenue growth and adjusted EPS guidance, while continuing to focus on strategic divestitures and high-growth segments to improve profitability.
Important takeaways from Medtronic’s (MDT) Q3 2026 earnings report
Shares of Medtronic Plc (NYSE: MDT) experienced a decline despite the company reporting better-than-expected Q3 2026 earnings. Investors were concerned about weaker margins and a cautious full-year outlook. However, Medtronic continues its tradition as a Dividend Aristocrat, signaling strong cash-flow generation and disciplined capital allocation.
Old National Bancorp to Issue Quarterly Dividend of $0.15 (NASDAQ:ONB)
Old National Bancorp (NASDAQ:ONB) has declared a quarterly dividend of $0.145 per share, payable on May 16th to shareholders of record on May 5th. This dividend represents an annualized yield of 2.3% with a payout ratio of 21.4%, indicating strong coverage by earnings. The bank recently surpassed Q4 EPS estimates with $0.62, though revenue slightly missed analyst expectations.
United Bancorp, Inc. (NASDAQ:UBCP) Announces Quarterly Dividend of $0.19
United Bancorp, Inc. (NASDAQ:UBCP) has declared a quarterly dividend of $0.1925 per share, representing a 1.3% increase from the previous quarter and an annualized yield of approximately 5.2%. The financial services provider has a consistent track record of raising its dividend annually for the past 13 years, with a payout ratio of 49%, indicating strong coverage by earnings. UBCP's stock recently traded at $14.76, with a market capitalization of $85.17 million and a price-to-earnings ratio of 11.02.
Abbott declares quarterly dividend of 63 cents per share
Abbott Laboratories has declared a quarterly dividend of 63 cents per share. This dividend is payable on May 15 to shareholders of record as of April 15. The announcement was made on February 20, 2026.
Medtronic’s blood pressure device wins coverage nod in Japan
Medtronic's Symplicity Spyral renal denervation system has received reimbursement approval in Japan, expanding access to its hypertension treatment. This decision follows a national coverage determination in the U.S. by CMS, and Medtronic is actively investing in market development for the device globally. The system uses radiofrequency energy to ablate nerves and lower blood pressure, offering a new device-based option for patients with uncontrolled hypertension.
Medtronic to cut 81 employees at California diabetes site
Medtronic (NYSE:MDT) is laying off 81 employees at its Northridge, California diabetes device facility, effective April 7, 2026. This restructuring comes as the company prepares to spin out its diabetes business, MiniMed, into a standalone public entity. The affected roles include engineering, IT, marketing, and technician positions, with Medtronic stating the cuts are necessary to ensure the new company's long-term success.
Forum Energy Technologies (NYSE:FET) Shares Gap Up After Better-Than-Expected Earnings
Forum Energy Technologies (NYSE:FET) gapped up after reporting better-than-expected quarterly earnings, with EPS of $0.41 against a $0.36 consensus and revenue of $202.2 million exceeding estimates. Despite the positive earnings surprise and stock price increase, the company maintains weak profitability with a negative net margin and return on equity. Analyst ratings are mixed, with a consensus of "Moderate Buy," and institutional investors have recently adjusted their positions in the stock.
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026
Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company's Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.
Vanguard Group Inc. Lowers Stock Position in Kimco Realty Corporation $KIM
Vanguard Group Inc. reduced its stake in Kimco Realty Corporation by 0.5% in the third quarter of 2025, selling 589,903 shares and retaining over 108 million shares valued at approximately $2.37 billion. Despite this sale, other institutional investors increased their holdings in Kimco Realty. The company has declared a quarterly dividend of $0.26 per share, and analysts rate Kimco as a "Moderate Buy" with a consensus target price of $24.18.
Vanguard Group Inc. Increases Stake in lululemon athletica inc. $LULU
Vanguard Group Inc. significantly increased its stake in lululemon athletica inc. by 3.9% during the third quarter, now owning 13.78 million shares valued at approximately $2.45 billion. This increase makes Vanguard one of the largest institutional holders of LULU stock, as other firms also adjusted their positions. Meanwhile, an insider sold a portion of her shares, and the company reported strong earnings, beating analyst estimates and providing optimistic FY2025 guidance, leading to an average analyst "Hold" rating with a target price of $227.05.
Medtronic PLC $MDT Shares Sold by Pekin Hardy Strauss Inc.
Pekin Hardy Strauss Inc. reduced its stake in Medtronic PLC by 37.8% in Q3, selling 16,404 shares and retaining 26,990 shares valued at approximately $2.57 million. Despite this, Medtronic reported strong quarterly earnings, surpassing analyst expectations with EPS of $1.36 and revenue of $9.02 billion, and issued positive FY2026 guidance. The company also maintains an annualized dividend of $2.84, offering a 2.9% yield, and holds an average "Moderate Buy" rating from analysts with an average price target of $111.05.
Medtronic (NYSE:MDT) Upgraded by Mizuho to "Strong-Buy" Rating
Mizuho upgraded Medtronic (NYSE:MDT) to a "strong-buy" rating, contributing to a "Moderate Buy" consensus among analysts with a $111.05 price target. The upgrade follows Medtronic's beat on Q3 earnings expectations and positive FY2026 guidance, driven by strong demand for heart devices. Despite overall positive sentiment from some analysts highlighting growth potential in cardiovascular and robotics, others express mixed views, trimming price targets due to legal and competitive challenges.
Medical Device Contract Manufacturing Market Is Going to Boom |• Flex Ltd. • Jabil Inc
Worldwide Market Reports has released a comprehensive research study on the "Medical Device Contract Manufacturing Market," forecasting its growth from 2026 to 2033. The report, based on primary and secondary research, details market drivers, challenges, opportunities, and the competitive landscape, including strategies of key players like Flex Ltd. and Jabil Inc. It also segments the market by device types and applications, providing regional analysis and strategic insights for stakeholders.
American Tower Corporation $AMT Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP significantly reduced its holdings in American Tower Corporation (NYSE:AMT) by 52.4% during the third quarter, while major shareholder Tower Corp /Ma/ also sold a substantial block of shares, decreasing their stake by over 91%. The article notes American Tower's high dividend payout ratio of 108.63%, which could impact the sustainability of its 3.7% yield. Analyst ratings for AMT are mixed, with a consensus of "Moderate Buy" and a target price of $218.79.
Factory Mutual Insurance Co. Acquires Shares of 57,852 AstraZeneca PLC $AZN
Factory Mutual Insurance Co. has acquired 57,852 shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, valued at approximately $4.438 million. AstraZeneca recently announced a dividend of $1.595 per share, payable on March 23rd, with a record date of February 20th and an ex-dividend date also on February 20th, representing a dividend yield of 153.0%. The company's stock opened at $208.76, has a market cap of $323.77 billion, and an average analyst rating of "Moderate Buy" with a target price of $95.75.
232,053 Shares in XPO, Inc. $XPO Purchased by Compass Wealth Management LLC
Compass Wealth Management LLC has acquired a new stake of 232,053 shares in XPO, Inc. (NYSE:XPO) during the 3rd quarter, valued at approximately $29.997 million. This makes XPO its third-largest holding, accounting for 3.5% of its portfolio and 0.20% of XPO's total shares. The report notes that XPO recently surpassed quarterly earnings and revenue estimates, is trading near its 12-month high, and has received multiple analyst upgrades, with a consensus "Moderate Buy" rating and a target price of $178.32.
Neurosurgery Market Is Going to Boom |Medtronic, Stryker Corporation, Zimmer Biomet, Johnson & Johnson
The global neurosurgery market is projected to grow from USD 4.10 billion in 2026 to USD 5.69 billion by 2033, exhibiting a CAGR of 4.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report by Coherent Market Insights provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
Zions Bancorporation National Association UT Sells 30,267 Shares of Zoetis Inc. $ZTS
Zions Bancorporation National Association UT significantly reduced its stake in Zoetis Inc. (NYSE:ZTS) in the third quarter, selling 30,267 shares to hold only 692 shares valued at $101,000. Despite this, Zoetis exceeded quarterly earnings expectations with an EPS of $1.48 and $2.39 billion in revenue, and provided optimistic FY2026 EPS guidance. The company, predominantly owned by institutional investors, also maintains a quarterly dividend and carries a consensus "Hold" rating from analysts.
Sunstone Hotel Investors (SHO) Expected to Announce Quarterly Earnings on Friday
Sunstone Hotel Investors (SHO) is scheduled to announce its Q4 2025 earnings before market open on Friday, February 27th, with analysts projecting $0.18 EPS and $226.18 million in revenue. Institutional investors hold 99.37% of the shares, with notable firms increasing their stakes. The stock currently has a "Hold" consensus rating and an average price target of $9.38.
Robotic Surgical Systems Market Is Going to Boom | Intuitive
Coherent Market Insights has published a new research report on the Robotic Surgical Systems Market, forecasting substantial growth from 2026 to 2033. The report offers a deep dive into market trends, drivers, and competitive landscapes, featuring key players like Intuitive Surgical, Medtronic, and Johnson & Johnson. It provides comprehensive segmentation, regional analysis, and strategic insights for businesses in the healthcare sector.
Arcellx (ACLX) Expected to Announce Earnings on Thursday
Arcellx (ACLX) is anticipated to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting a loss of ($1.01) per share. The company's stock has a market cap of $3.99 billion and a negative P/E ratio, while insiders have recently sold shares. Despite some downgrades, the consensus analyst rating remains "Moderate Buy" with an average price target of $109.20.
Farmland Partners Inc. (NYSE:FPI) Increases Dividend to $0.09 Per Share
Farmland Partners Inc. (NYSE:FPI) has announced a quarterly dividend increase to $0.09 per share, a 50% rise from its previous dividend, resulting in an approximate 3.0% yield. Despite a strong earnings report where EPS of $0.43 exceeded expectations and revenues surpassed estimates, the company's dividend payout ratio of 150% indicates that the distribution is not fully covered by current earnings and relies on its balance sheet. Analysts currently maintain a "Hold" rating on the stock, with the company providing FY2026 EPS guidance between $0.33 and $0.37.
Do Integer’s Mixed 2025 Results and 2026 Guidance Reframe Its Profitability Story for ITGR Investors?
Integer Holdings reported higher Q4 2025 sales but lower full-year net income compared to the previous year, alongside new 2026 guidance. While Q4 earnings were strong, the overall 2025 profit was softer, and the 2026 outlook factors into ongoing investor concerns and a shareholder investigation. This creates a mixed narrative for investors regarding future profitability and growth sustainability.
Tilray Brands (NASDAQ:TLRY) Stock Price Up 4.1% - Time to Buy?
Tilray Brands (NASDAQ:TLRY) saw its stock price jump 4.1% intraday on Thursday, trading at $7.89, though with volume 50% below its average. Despite this increase, analysts generally hold a "Hold" rating for the cannabis company, with an average price target of $13.33, and the company's fundamentals remain weak, including negative EPS, net margin, and trading below its 50-day and 200-day moving averages. Institutional investors have been active, with significant increases in holdings by some, emphasizing the mixed sentiment surrounding TLRY.
ISRG's International Growth Outpaces US With 35% Procedure Volume
Intuitive Surgical (ISRG) is experiencing significant international growth, with procedures outside the US climbing 23% in 2025, outpacing its 15% domestic growth. This international expansion, driven by improved market access and training, now accounts for 35% of total global procedures. Other medtech companies like Medtronic and Abbott are also seeing international markets as key growth drivers, demonstrating a broader trend in the industry.
Tandem Diabetes faces earnings test as profitability questions loom By Investing.com
Tandem Diabetes Care (NASDAQ: TNDM) is preparing to release its fourth-quarter results, with market observers keen on its path to sustained momentum and eventual profitability. Analysts anticipate a narrower loss and increased revenue compared to the previous quarter, with EPS estimates rising 4.3% over the past 60 days. Despite a bullish stance from Wall Street analysts with a consensus "Buy" rating, the company's shares have declined significantly over the past year.
Urban Outfitters (NASDAQ:URBN) Earns "Outperform" Rating from Telsey Advisory Group
Telsey Advisory Group reiterated an "Outperform" rating for Urban Outfitters (NASDAQ:URBN) with a $98 price target, indicating a potential 39.7% upside. The stock, which currently trades near $70 with a $6.29B market cap and a P/E of 13.23, has a mixed analyst consensus of "Hold" and an average target price of $86.67. Insider transactions show CEO Richard A. Hayne selling shares, though insiders still own 31.6% of the company's stock.
SAIC Launches Alliance to Accelerate State-Led Execution of $50 Billion Rural Healthcare Transformation Program
SAIC has formed the Alliance for Advancing Rural Healthcare (AARH) with seven other organizations to help state governments implement the $50 billion federal Rural Health Transformation (RHT) Program. This initiative aims to address community healthcare challenges in rural areas by integrating capabilities in IT, data, mobile care, education, and pharmacy services. The alliance seeks to translate financial investments into sustainable improvements in access to care, modernized systems, and expanded healthcare workforce capacity across rural America.
Bernstein cuts Insulet stock price target on competition concerns
Bernstein SocGen Group has lowered its price target for Insulet Corporation (NASDAQ:PODD) to $330 from $380, while maintaining an Outperform rating, due to increasing competition in the insulin pump market. Despite Insulet's strong revenue growth and financial health, investor concerns about competitive patch pumps and potential pricing pressure have led to an underperformance of its shares. The new price target reflects conservatism and investor worries, even as Bernstein sees upside potential from Type 2 diabetes execution and margin expansion.
